Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Colorectal Neoplasms 30Carcinoma, Hepatocellular 17Ovarian Neoplasms 14Fallopian Tube Neoplasms 10Carcinoma, Non-Small-Cell Lung 9Neoplasms 8Glioblastoma 7Liver Neoplasms 6Lung Neoplasms 5Colonic Neoplasms 5Breast Neoplasms 5Neoplasm Metastasis 4Carcinoma, Renal Cell 4Brain Neoplasms 4Stomach Neoplasms 3Rectal Neoplasms 3Melanoma 3Carcinoma, Ovarian Epithelial 3Carcinoma 3Squamous Cell Carcinoma of Head and Neck 2Sarcoma 2Parkinson Disease 4, Autosomal Dominant Lewy Body 2Nasopharyngeal Neoplasms 2Nasopharyngeal Carcinoma 2Lymphoid Interstitial Pneumonia 2Colorectal Cancer Metastatic 2Brenner Tumor 2Advanced Solid Tumors 2Adenocarcinoma, Mucinous 2Virus Diseases 1

Interventions

trastuzumab deruxtecan 1sintilimab 1pembrolizumab 1durvalumab 1cabozantinib 1Drug Therapy 1Bevacizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × Gastric Adenocarcinoma × Bevacizumab × Clear all
NCT06667050 2024-10-31

CAPOX Plus Sintilimab and Bevacizumab Biosimilar (IBI305) for Neoadjuvant Treatment of Locally Advanced Gastric Cancer

West China Hospital

Phase 2 Active not recruiting
58 enrolled
Gastrointestinal

Gastric Adenocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡